Research graph
References from CC-486 plus venetoclax: another step toward oral AML therapy. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1182/bloodadvances.2026020179 · 2026 · Admitted local publication
Efficacy and biologic correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia
10.1158/2159-8290.cd-16-0313 · 2016 · External reference
Inhibition of amino acid metabolism selectively targets human leukemia stem cells
10.1016/j.ccell.2018.10.005 · 2018 · External reference
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020 · External reference
Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 study
10.1016/s2352-3026(24)00033-4 · 2024 · External reference
Unresolved reference
External reference
Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission
10.1056/nejmoa2004444 · 2020 · External reference
A phase 2 dose confirmation trial of oral ASTX030, a combination of oral azacitidine with cedazuridine among patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
10.1182/blood-2025-491 · 2025 · External reference
Unresolved reference
External reference
